Outcome for young high-risk aggressive B-cell lymphoma patients treated with CHOEP-14 and rituximab (R-CHOEP-14)
To study the effectiveness and tolerability of a dose-intensified treatment including rituximab for patients, not older than 65 yr, with high-risk aggressive B-cell lymphoma.
Thirty-eight patients with high-risk aggressive B-cell lymphoma, the majority classified as grade 2 or 3 using age-adjusted International Prognostic Index, were treated with six courses of CHOEP+rituximab on a 2-wk schedule with G-CSF d 4-11. CNS prophylaxis was administered using intravenous Ara-C as a single dose at the end of treatment.
All patients were considered responders after three courses. Thirty-one patients (82%) achieved a complete remission or a complete remission unverified. With a median follow up of 27 mo, overall and event-free survival are 79% and 60%, respectively. Treatment was given on an outpatient basis. There were no treatment-related unexpected toxic events or mortalities. Large-cell lymphoma involvement of the bone marrow was a poor prognostic sign even with this intensified treatment and 4/6 patients relapsed. CNS relapse occurred in three patients, two of whom had large cell bone marrow involvement.
Although only a short follow up, the R-CHOEP-14 regimen is promising and could be an improvement compared to conventional treatment, with acceptable toxicity. The value of intravenous Ara-C at the end of treatment can be questioned, as it did not prevent CNS relapse or affect treatment outcome.
Key WordsHigh-risk aggressive B-cell lymphoma dose-intensified treatment rituximab
Unable to display preview. Download preview PDF.
- 17.Reyes F, et al. Failure of first line induction high-dose chemotherapy in poor prognosis patients with aggressive lymphoma; updated results of the randomized LNH93-3 study (abstract 2640). Blood 1997; 90(Suppl 2): 594.Google Scholar
- 18.Cuttica A, et al. Patients with high-risk aggressive lymphoma treated with frontline intensive chemotherapy and autografting: evidence of marked differences in outcome between patients with age-adjusted International Prognostic Index scores 2 and 3. Cancer 2003; 98(5): 983–992.PubMedCrossRefGoogle Scholar
- 21.Habermann TM, et al. Phase III trial of rituximab-CHOP (R-CHOP) vs CHOP with a second randomization to main-tenance rituximab (MR) or observation in patients 60 years of age and older with diffuse large B-cell lymphoma (DLBCL) (abstract 8). Blood 2003; 102: 6.Google Scholar
- 23.Pfreundschuh M, et al. First analysis of the completed mabthera international (MinT) trial in young patients with low-risk diffuse large B-cell lymphoma (DLBCL): addition of rituximab to a CHOP-like regimen significantly improves outcome of all patients with the identification of a very favourable subgroup with IPI=0 and no bulky disease (abstract 157). Blood 2004; 104: 48.Google Scholar
- 27.Glantz MJ, et al. Randomized trial of a slow-term release versus standard formulation of cytarabine for the intrathecal treatment of lymphomatosous meningitis. J Clin Oncol 2000; 18(9): 2003–2004.Google Scholar